Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

被引：0
|
作者：
Qiuling Zhao
Ruixiang Xie
Wanfu Zhong
Wenbin Liu
Ting Chen
Xiuliang Qiu
Lin Yang
机构：
[1] Clinical Oncology School of Fujian Medical University,Department of Pharmacy
[2] Fujian Cancer Hospital,Department of Pharmacy
[3] Fujian University of Traditional Chinese Medicine,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
Durvalumab; PD-L1; Biliary tract cancer; First-line treatment; Cost-effectiveness analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Bouattour, Mohamed
    Valle, Juan W.
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard A., III
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David Bing
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 531 - 531
  • [42] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States
    Qu, T.
    Zhong, Y.
    Zhang, S.
    Meng, Y.
    Joo, S.
    Shah, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1059 - S1060
  • [44] META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY VERSUS IRINOTECAN-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC ADVANCED COLORECTAL CANCER IN CHINA
    Zhang, X.
    Su, W.
    Lin, Z.
    Jian, Y.
    Xuan, J.
    VALUE IN HEALTH, 2022, 25 (01) : S66 - S67
  • [45] Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Burris, Howard A., III
    Okusaka, Takuji
    Vogel, Arndt
    Lee, Myung Ah
    Takahashi, Hidenori
    Breder, Valeriy Vladimirovich
    Blanc, Jean-Frederic
    Li, Junhe
    Watras, Magdalena
    Xiong, Julia
    Abraham, Jayne
    Patel, Nikunj
    Wang, Julie
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
    Chen, Ruijia
    Zhang, Yalan
    Lin, Kongying
    Huang, Defu
    You, MaoJin
    Lai, Yanjin
    Wang, Jinye
    Hu, Yingying
    Li, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study
    Pelzer, U.
    He, A. R.
    Tan, B.
    Suksombooncharoen, T.
    Takahashi, H.
    Chen, M. -H.
    Ostwal, V.
    Oh, S. C.
    Sezer, E.
    Potemski, P.
    Rau, K. -M.
    Sirachainan, E.
    Li, J.
    Blanc, J. -F.
    Cohen, G.
    Zotkiewicz, M.
    Rokutanda, N.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 59 - 60
  • [48] Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
    Okusaka, T.
    Kitano, M.
    Chen, M-H.
    Chen, J-S.
    Ostwal, V. S.
    McNamara, M. G.
    Breder, V.
    Petrova, M.
    Buchschacher, G.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1471 - S1471
  • [49] FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
    Ulusakarya, A.
    Karray, W.
    Abdou, J.
    Karaboue, A.
    Haydar, M.
    Krimi, S.
    Gumus, Y.
    Almohamad, W.
    Goldschmidt, E.
    Biondani, P.
    Morere, J. F.
    ANNALS OF ONCOLOGY, 2018, 29 : 260 - 260
  • [50] A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
    Filippi, Roberto
    Montagnani, Francesco
    Lombardi, Pasquale
    Fornaro, Lorenzo
    Aprile, Giuseppe
    Casadei-Gardini, Andrea
    Faloppi, Luca
    Palloni, Andrea
    Satolli, Maria Antonietta
    Scartozzi, Mario
    Citarella, Fabrizio
    Lutrino, Stefania Eufemia
    Vivaldi, Caterina
    Silvestris, Nicola
    Rovesti, Giulia
    Rimini, Margherita
    Aglietta, Massimo
    Brandi, Giovanni
    Leone, Francesco
    ACTA ONCOLOGICA, 2021, 60 (10) : 1317 - 1324
12345